Related Experiment Video

Updated: Jul 15, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy

Vassiliki Papadimitrakopoulou1, Alex A Adjei

  • 1MD Anderson Cancer Center, Houston, Texas 77030, USA. vpapadim@mdanderson.org

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|April 6, 2007
PubMed

Insights

Lung cancer involves aberrant signaling pathways. Targeting key proteins like mTOR, Akt, and MEK shows promise for new lung cancer therapies, with early clinical data emerging.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Aberrant intracellular signaling, including mutations, oncogenic activation, and gene amplification, is a hallmark of lung cancer.
  • Key signaling proteins such as mammalian target of rapamycin (mTOR), protein kinase B (Akt), and mitogen-activated protein kinase kinase (MEK) are implicated in lung cancer pathogenesis.
  • These proteins represent attractive therapeutic targets for lung cancer treatment.

Purpose of the Study:

  • To review current therapeutic strategies targeting mTOR, Akt, and MEK in lung cancer.
  • To summarize early clinical data for these targeted therapies in lung cancer patients.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of data on the manipulation of mTOR, Akt, and MEK signaling pathways.
  • Compilation of early clinical trial results for lung cancer.

Main Results:

  • The review details the rationale for targeting mTOR, Akt, and MEK in lung cancer.
  • Early clinical data suggest potential efficacy of therapies aimed at these signaling proteins.
  • Further investigation is warranted to optimize treatment strategies.

Conclusions:

  • Targeting intracellular signaling pathways, specifically mTOR, Akt, and MEK, is a viable therapeutic approach for lung cancer.
  • Early clinical findings support the continued development of these targeted therapies.
  • Personalized treatment strategies based on specific pathway alterations may improve outcomes in lung cancer.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...